DBL

Dia Beta Labs (DBL) is a UK-based biotechnology company focused on developing next-generation therapeutics for metabolic diseases, including obesity and type 2 diabetes. A spin-out from Ulster University, the company leverages over 30 years of research into pancreatic health and beta-cell function to address the root causes of metabolic decline. Its lead candidate, DBL002, is a novel peptide analogue designed to promote sustainable weight loss by targeting fat while sparing muscle mass, while simultaneously improving pancreatic beta-cell health. Unlike traditional GLP-1 agonists that primarily manage symptoms, DBL's approach focuses on reversing disease progression and preventing long-term complications. The company is currently advancing its pipeline toward clinical trials and has secured significant seed funding from investors such as DSW Ventures and QUBIS.